OncoMatch/Clinical Trials/NCT07785180
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
Is NCT07785180 recruiting? Yes, currently enrolling (Sep 2026). Studying Chemotherapy for blastic plasmacytoid dendritic cell neoplasm (bpdcn).
Treatment: Chemotherapy — The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study (STML-401-0521).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: CD4 expression
demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123
Required: CD56 expression
demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123
Required: IL3RA expression
demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123
Prior therapy
Must have received: chemotherapy — first-line treatment for BPDCN
treated with chemotherapy regimens (at a minimum) as first-line treatment for BPDCN from May 2016
Cannot have received: investigational agent
Participant has received an investigational agent as first-line therapy for BPDCN
Cannot have received: first-line therapy for BPDCN in an interventional clinical trial
Participant has received first-line therapy for BPDCN in an interventional clinical trial
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07785180 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent, first-line therapy for BPDCN in an interventional clinical trial disqualifies patients from enrollment.
Does this trial require CD4?
Yes, CD4 expression is a required biomarker for enrollment.
Does this trial require CD56?
Yes, CD56 expression is a required biomarker for enrollment.
Does this trial require IL3RA?
Yes, IL3RA expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify